

Curriculum Vitae

Personal information **Agata Mikolajewska**

Work experience

February 2021-present: Research associate in the Robert Koch Institute, Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response (ZBS7), Clinical Management and Infection Control (ZBS7.1), Berlin, Germany

Main activities:

- Coordination of work in STAKOB (Permanent Working Group of Competence and Treatment Centres for high consequence infectious diseases, www.rki.de/stakob) and the COVRIIN specialist group (Advisory Group for Intensive Care, Infectious Diseases and Emergency Medicine, www.rki.de/covriin)
- Development of concepts and training on functional and procedural hygiene management for dealing with patients who are ill due to highly pathogenic pathogens or biological toxins
- Needs analysis for vaccines and other medicines
- Advising medical facilities on the occurrence of diseases caused by highly pathogenic pathogens and biological toxins (with STAKOB)
- Preparation of therapy concepts for special pathogens, together with expert association and STAKOB
- Cross-departmental collaboration in the Long COVID Group and collaboration with other departments at the Robert Koch Institute, e.g. the STIKO office (Standing Committee on Vaccination)
- Participation in the operational unit "Clinic Advisory Group" with on-site support in a biological hazard situation

March 2015-December 2021: Physician in the Medical Clinic for Infectious Diseases and Respiratory Medicine, Charité Berlin, Germany

Main activities:

- Physician on the High Level Isolation Unit (HLIU) (STAKOB treatment centre Berlin)
- Infectiological consultation service and antibiotic stewardship
- Coordination of clinical studies in the field of infectiology and pneumology
- Management of PROGRESS (Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis; <https://www.progress-net.de/>)
- Member of the COVRIIN specialist group (Advisory Group for Intensive Care, Infectious Diseases and Emergency Medicine, www.rki.de/covriin)
- Participation in the CEOsys project (COVID-19 evidence ecosystem, <https://covid-evidenz.de/>)

May 2009-February 2015: Physician in the Department of Hematology, Oncology and Cancer Immunology, Charité Berlin, Germany

Main areas of activity:

- Breast cancer outpatient clinic
- Haematology outpatient clinic
- Haematology ward
- Infections in immunocompromised patients, focus: fungal infections

January 2006-April 2009: Physician in the Department of Hematology, Oncology, Haemostaseology, Leipzig University Hospital, Leipzig, Germany

Main areas of activity:

- autologous and allogeneic stem cell transplantations
- Infections in immunocompromised patients, focus: fungal infections

Education and training

- **February 2017:** Specialist in internal medicine, Berlin, Germany
- **Mai 2007:** Dissertation at the Medical Faculty of Saarland University, Homburg/Saar, Germany. Dissertation topic: "Glioma-associated antigen 2 (GLEA2) as an immunogen. Aspects of the humoral and cellular immune response."
- **October 2004-October 2005:** Medical studies at the Medical Faculty of Saarland University, Homburg (Saar), Germany
- **November 2002-September 2004:** Scholarship holder of the German Research Foundation (DFG) as part of the Research Training Group "Cellular Regulation and Growth" at the Medical Faculty of Saarland University in Homburg/Saar at the Institute of Human Genetics
- **November 1996-October 2002:** Medical studies at the Medical University in Wrocław, Poland
- **October 2000-July 2001:** Medical studies at the Medical Faculty of the Humboldt University of Berlin, Germany

Additional information

Publications

Selected relevant publications:

- Dorner MB, Wilking H, Skiba M, Wilk L, Steinberg M, Worbs S, Çeken S, Kaygusuz S, Simon S, Becher F, **Mikolajewska A**, Kornschöber C, Büttler T, Jourdan-Da-Silva N, An der Heiden M, Schaade L, Stark K, Dorner BG, Frank C. A large travel-associated outbreak of iatrogenic botulism in four European countries following intragastric botulinum neurotoxin injections for weight reduction, Türkiye, February to March 2023. *Euro Surveill.* 2023 Jun;28(23):2300203. doi: 10.2807/1560-7917.ES.2023.28.23.2300203. PMID: 37289431; PMCID: PMC10318948.
- Dahms K, **Mikolajewska A**, Ansems K, et al. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. *Eur J Med Res.* 2023 Feb 25; 28(1):100. doi: 10.1186/s40001-023-01072-z. PMID: 36841793; PMCID: PMC9959952.
- **Mikolajewska A**, Kling K, Piechotta V, et al.: Wissenschaftliche Begründung der STIKO zur Aktualisierung der Empfehlung zur SARS-CoV-2-Prä-Expositionsprophylaxe mit Tixagevimab/Cilgavimab (Evusheld). *Epid Bull* 2023; 8:39-44 | DOI 10.25646/11164
- Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, **Mikolajewska A**, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. *Cochrane Database Syst Rev.* 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2. PMID: 36695483; PMCID: PMC9875553.
- Kurth F, Tober-Lau P, Lingscheid T, Bardtke L, Kim J, Angheben A, Gobbi FG, Mbavu L, Stegemann MS, Heim KM, Pfäfflin F, Menner N, Schürmann M, **Mikolajewska A**, Witznath M, Sander LE, Mayer B, Zoller T. Post-treatment haemolysis is common following oral artemisinin combination therapy of uncomplicated malaria in travellers. *J Travel Med.* 2023 Jan 5: taad001. doi: 10.1093/jtm/taad001. Epub ahead of print. PMID: 36611010.
- Wagner C, Griesel M, **Mikolajewska A**, Mueller A, Nothacker M, Kley K, Metzendorf MI, Fischer AL, Kopp M, Stegemann M, Skoetz N, Fichtner F. Systemic corticosteroids for the treatment of COVID-19. *Emergencias.* 2022 Dec; 34(6):468-470. English, Spanish. PMID: 36625698.
- Wagner C, Griesel M, **Mikolajewska A**, Metzendorf MI, Fischer AL, Stegemann M, Spagl M, Nair AA, Daniel J, Fichtner F, Skoetz N. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. *Cochrane Database Syst Rev.* 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2. PMID: 36385229; PMCID: PMC9670242.
- Kreuzberger N, Hirsch C, Andreas M, Böhm L, Bröckelmann PJ, Di Cristanziano V, Golinski M, Hausinger RI, Mellinshoff S, Lange B, Lischetzki T, Kappler V, **Mikolajewska A**, Monsef I, Park YS, Piechotta V, Schmaderer C, Stegemann M, Vanshyla K, Weber F, Weibel S, Stephani C, Skoetz N. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. *Cochrane Database Syst Rev.* 2022 Aug 9;8(8):CD015021. doi: 10.1002/14651858.CD015021. PMID: 35943061; PMCID: PMC9361430.
- Kramer A, Prinz C, Fichtner F, Fischer AL, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf MI, Golinski M, Moerer O, Stephani C, **Mikolajewska A**, Kluge S, Stegemann M, Laudi S, Skoetz N. Janus kinase inhibitors for the treatment of COVID-19. *Cochrane Database Syst Rev.* 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209. PMID: 35695334; PMCID: PMC9190191.
- Griesel M, Wagner C, **Mikolajewska A**, Stegemann M, Fichtner F, Metzendorf MI, Nair AA, Daniel J, Fischer AL, Skoetz N. Inhaled corticosteroids for the treatment of COVID-19. *Cochrane Database Syst Rev.* 2022 Mar 9;3(3): CD015125. doi: 10.1002/14651858.CD015125. PMID: 35262185; PMCID: PMC8905579.
- Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, **Mikolajewska A**, Kranke P, Meybohm P, Skoetz N, Weibel S. Antibiotics for the treatment of COVID-19. *Cochrane Database Syst Rev.* 2021 Oct 22;10(10):CD015025. doi: 10.1002/14651858.CD015025. PMID: 34679203; PMCID: PMC8536098.
- **Mikolajewska A**, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. *Cochrane Database Syst Rev.* 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045. PMID: 34658014; PMCID: PMC8521385.
- Stroehlein JK, Wallqvist J, Iannizzi C, **Mikolajewska A**, Metzendorf MI, Benstoem C, Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. *Cochrane Database Syst Rev.* 2021 May 24;5(5): CD015043. doi: 10.1002/14651858.CD015043. PMID: 34029377; PMCID: PMC8406457.
- Buchholz U, (...), **Mikolajewska A**, Moos V, Naumann MB, Pankow W, Scherübl H, Schmidt B, Schneider T, Stocker H, Suttrop N, Thiemig D, Gollnisch C, Mannschatz U, Haas W, Schaefer B, Lück C. Source attribution of community-acquired cases of Legionnaires' disease-results from the German LeTriWa study; Berlin, 2016-2019. *PLoS One.* 2020 Nov 25;15(11):e0241724. doi: 10.1371/journal.pone.0241724.
- Elges S, Arnold R, Liesenfeld O, Kofla G, **Mikolajewska A**, Schwartz S, Uharek L, Ruhnke M. Prospective evaluation of the SeptiFAST multiplex real-time PCR assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an in-house real-time PCR method. *Mycoses.* 2017 Dec;60(12):781-788. doi: 10.1111/myc.12662. Epub 2017 Sep 19
- Ruhnke M, **Mikolajewska A**. The challenge of systemic candida infections. Online: PRACTICAL THERAPEUTICS, hospitalpharmacyeurope.com, 16 February, 2015
- **Mikolajewska A**, Schwartz S, Ruhnke M. [Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy.](#) *Mycoses.* 2012 Jan;55(1):2-16. doi: 10.1111/j.1439-0507.2010.01961.x. Epub 2011 May 9. Review.
- **Mikolajewska A**, Genzel G, Borte G, Niederwieser D, Lange T. Complete Resolution of a Pulmonary Aspergillosis on Third-Line Posaconazole and Immunosuppression Taper After Allogeneic Hematopoietic Cell Transplantation. *Infect Dis Clin Pract* 2009; 17: 339-341

Projects

Memberships

Member of the German Society for Infectiology (DGI), German Society for Internal Medicine (DGIM), German Association of Internists (BDI)

Other Relevant Information